Back to Results

Psyence Biomedical Ltd (PBM)

Psyence Biomedical Ltd. is a Toronto-based biotechnology company focused on the development of botanical psilocybin-based medicines. Its lead candidate, PEX010, is a naturally sourced psilocybin capsule being studied in a Phase IIb clinical trial for anxiety and depression, along with related conditions such as post-traumatic stress disorder, stress, grief, and adjustment disorder in palliative care settings. The company is also evaluating natural psilocybin for adjustment disorder in patients with incurable cancer. Psyence Biomedical has partnered with iNGENu Pty Ltd on a Phase IIb study of PEX010 in psilocybin-assisted psychotherapy for adjustment disorder linked to incurable cancer, and it has a strategic collaboration with PsyLabs to produce ibogaine. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-PBM
$5.61
-15.3% Downside
Fair
Not available
Not available
Fair
0.0%
November 20, 2026
1.5x
25.27 M
9.764 M
0.0%
68.4%
20.8
117.4%
Valuation • Fair Value

Psyence Biomedical Ltd (NASDAQ-PBM) Fair Value by Valuation Model

Review the available estimates for Psyence Biomedical Ltd (NASDAQ-PBM), including Comps Fair Value.

Primary Valuation Read

Fair Value

$5.61

Estimated downside of 15.3% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$5.61

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Psyence Biomedical Ltd (NASDAQ-PBM) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Psyence Biomedical Ltd (NASDAQ-PBM)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-6.232 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Psyence Biomedical Ltd (NASDAQ-PBM) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Psyence Biomedical Ltd (NASDAQ-PBM)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

20.8

Relatively strong balance-sheet zone.

FCF / Net Income

117.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Psyence Biomedical Ltd (NASDAQ-PBM). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Psyence Biomedical Ltd (NASDAQ-PBM)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 20, 2026

Days to Earnings

63

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Psyence Biomedical Ltd (NASDAQ-PBM), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Psyence Biomedical Ltd (NASDAQ-PBM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Psyence Biomedical Ltd (NASDAQ-PBM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Psyence Biomedical Ltd (NASDAQ-PBM) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Buy

The weekly technical read for Psyence Biomedical Ltd (NASDAQ-PBM) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Psyence Biomedical Ltd (NASDAQ-PBM) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Psyence Biomedical Ltd (NASDAQ-PBM) Stock FAQ

Data-supported answers about Psyence Biomedical Ltd (NASDAQ-PBM), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$5.61
Estimated downside 15.3%
Valuation Rating
Overvalued
Estimated downside of 15.3%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Psyence Biomedical Ltd (NASDAQ-PBM) is $5.61. This implies an estimated downside of 15.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 15.3% versus the current market price.

The current financial health read for Psyence Biomedical Ltd (NASDAQ-PBM) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Psyence Biomedical Ltd (NASDAQ-PBM) is November 20, 2026.

The latest available data indicates no current dividend yield for Psyence Biomedical Ltd (NASDAQ-PBM).

The current market capitalization listed for Psyence Biomedical Ltd is 25.27 M.

The current enterprise value listed for Psyence Biomedical Ltd is 9.764 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Psyence Biomedical Ltd is NASDAQ-PBM, and the stock is listed on NASDAQ.

Psyence Biomedical Ltd (NASDAQ-PBM) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Psyence Biomedical Ltd is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Psyence Biomedical Ltd is 68.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B